SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001213900-24-060604
Filing Date
2024-07-10
Accepted
2024-07-10 20:34:52
Documents
2
Group Members
ANASTASIS NIKOLAOUANDREAS HADJIMICHAELMARCIN CZERNIKWIACZESLAW SMOLOKOWSKI

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 2 TO SCHEDULE 13G ea0208963-13ga2chione_acri.htm SC 13G/A 87322
2 JOINT FILING AGREEMENT, DATED JULY 10, 2024, AMONG THE REPORTING PERSONS ea020896302ex99-1_acrivon.htm EX-99.1 3939
  Complete submission text file 0001213900-24-060604.txt   92937
Mailing Address SIMOU MENARDOU 8, RIA COURT 8 OFFICE 101, 6015 LARNACA G4 CY
Business Address SIMOU MENARDOU 8, RIA COURT 8 OFFICE 101, 6015 LARNACA G4 CY 48 (22) 840 8342
Chione Ltd (Filed by) CIK: 0001590232 (see all company filings)

IRS No.: 000000000 | State of Incorp.: G4
Type: SC 13G/A

Mailing Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472
Business Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 617-207-8979
Acrivon Therapeutics, Inc. (Subject) CIK: 0001781174 (see all company filings)

IRS No.: 825125532 | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-93824 | Film No.: 241110900
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)